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Nonsense mutations that occur more than 50 bases upstream of
terminal spliced junctions are generally thought to lead to
degradation of the corresponding transcripts by the process of
nonsense-mediated mRNA decay. It has also been proposed
that some nonsense mutations may affect splicing by the
process of nonsense-associated altered splicing (NAS), or by
the disruption of a splicing regulatory element. In this study, the
effect of the R553X mutation on the splicing of exon 11 of the
cystic fibrosis transmembrane conductance regulator gene was
investigated. Evidence that R553X causes exon 11 to skip
through the creation of a putative exonic splicing silencer (ESS)
was provided. The putative ESS appears to be active when
located immediately upstream of a 59 splice site. These findings
argue against the possibility that R553X-associated exon 11
skipping is caused by NAS. The study further suggests that
aminoglycoside antibiotic treatment would not be effective for
patients with the R553X mutation, owing to the skipping of exon
11, and further emphasises the need for detailed mechanistic
characterisation of the consequences of nonsense disease
mutations.
C
ystic fibrosis is the most common autosomal recessive
disease in the Caucasian population.1 Cystic fibrosis is
characterised, in its classic form, by chronic obstructive
pulmonary disease, exocrine pancreatic insufficiency, increased
sweat chloride electrolytes and male infertility.1 The primary
cause is a defect in chloride and sodium transport in cystic
fibrosis secretory epithelial cells due to mutations in the cystic
fibrosis transmembrane conductance regulator (CFTR) gene.
The CFTR gene consists of 27 exons that span approximately
200 kb of genomic sequence located on the long arm of human
chromosome 7.2 To date, over 1400 CFTR mutations have been
identified (http://www.genet.sickkids.on.ca/cftr/). Significant
genotype–phenotype correlation has been observed between
CFTR mutations and pancreatic function,3 but it has also been
recognised that secondary genetic factors modulate the severity
of a subset of cystic fibrosis-associated symptoms.4–7
Of the CFTR mutations identified, 10.2% are nonsense
mutations and involve nucleotide changes that would appar-
ently result in the creation of premature termination codons
(PTCs) (http://www.genet.sickkids.on.ca/cftr/). These muta-
tions are associated with pancreatic insufficiency and a
generally severe cystic fibrosis phenotype.8 Transcripts contain-
ing nonsense mutations are typically degraded by a quality
control mechanism known as nonsense-mediated mRNA decay
(NMD) to prevent the synthesis of truncated proteins that may
otherwise exert dominant negative effects.9 10 Examples of
CFTR nonsense mutations that generate reduced transcript
levels include G542X and Y1092X.11 There are also examples of
nonsense mutations that cause skipping of the exon in which
they reside such as the CFTR R75X11 and R553X mutations.12
Two different mechanisms have been proposed to explain how
nonsense mutations cause exon skipping more often than other
types of mutations. The first proposed mechanism, known as
nonsense-associated altered splicing (NAS), could involve a
scanning process that monitors the open reading frame for
PTCs before splicing occurs, promoting skipping of the exon in
which the PTC is located.13–15 The second proposed mechanism,
which is supported by more extensive evidence, involves the
inactivation of exonic splicing enhancers (ESEs), which are
short and degenerate sequences that promote the selection of
proximal splice sites in constitutive and alternative exons.16 It is
of interest to note that purine-rich codons (eg, GAA, GGA and
AAG) which often overlap strong ESEs17 can be mutated by a
single base to the PTCs TAA, TGA and TAG, respectively.
Evidence that such mutations disrupt ESE function has been
reported.16 18
In addition to ESEs, other splicing elements are known to
regulate the inclusion of exons. These include intronic splicing
enhancers, and, exonic or intronic splicing silencers, which
regulate the selection of splice sites and are often bound by
proteins that interfere with the recruitment of the spliceosome
to splice sites.19 Two recent studies have identified groups of
exonic splicing silencers (ESSs) using bioinformatics20 and
systematic evolution of ligands by exponential enrichment21
approaches. The first study identified sequences more fre-
quently present in pseudoexons than in authentic exons and
showed that these sequences promoted exon skipping in a
reporter system.20 The second study identified sequences from
random pools of hexamers and decamers that prevented the
inclusion of an exon and were enriched in pseudoexons
compared with constitutive exons.21 In follow-up experiments,
the mode of action of ESSs was investigated and shown to be
position dependent with respect to splice sites.22
Studies have shown that diseases such as cystic fibrosis
caused by nonsense mutations may be treated with aminogly-
coside antibiotics.23 24 Aminoglycoside antibiotics suppress
translational fidelity, resulting in partial expression of the
mutated allele. Thus, it is paramount to determine whether
stable transcripts are generated from nonsense mutation-
containing genes, and to understand the mechanism under-
lying the disruptive effects of these mutations. To date, distinct
results about the effect of the third most common nonsense
mutation, R553X, on the CFTR transcript have been
Abbreviations: CFTR, cystic fibrosis transmembrane conductance
regulator; ESE, exonic splicing enhancer; ESS, exonic splicing silencer;
GAPDH, glyceraldehyde-3-phosphate dehydrogenase; HEK, human
embryonic kidney; IB3, human bronchial epithelial; NAS, nonsense-
associated altered splicing; NMD, nonsense-mediated mRNA decay;
29OMeAO, 29-O-methyl antisense oligonucleotides; PTC, premature
termination codon; RT-PCR, reverse transcriptase-polymerase chain
reaction
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reported.12 25 26 In this report, we have carried out a detailed
analysis to determine the mechanism by which the CFTR
R553X mutation alters gene expression in patients with cystic
fibrosis. We provide evidence that the R553X mutation results
in the creation of a putative ESS element that acts on 59 splice
site selection leading to exclusion of exon 11.
MATERIALS AND METHODS
The study group consisted of five patients diagnosed with cystic
fibrosis based on the presence of clinical symptoms character-
istic for the disease.1 All patients were compound heterozygotic
for DF508 (1652del3, exon 10) and R553X (1789CRT)
mutations. Control samples were obtained from healthy
individuals and did not carry CFTR mutations. The study was
approved by the Human Subjects Review Board of The Hospital
for Sick Children.
Total RNA was extracted from cultured lymphoblastoid cells
treated with cycloheximide (100 mg/ml in DMSO) or DMSO
only for 4 h before harvesting, using RNeasy extraction kit
(Qiagen). First strand cDNA was synthesised from 2–3 mg of
total RNA by oligo-dT-primed reverse transcription with
superscript II reverse transcriptase (Invitrogen) according to
the supplier’s directions. A PCR was then performed to generate
a fragment spanning exons 10, 11 and 12 of the CFTR transcript
using primers X10-5, 59-GAG GGT AAA ATT AAG CAC AG-39
and X12-3s, 59-AGG TAT CCA AAA GGA GAG TC-39, and, a
fragment spanning exons 7 and 8 of the glyceraldehyde-3-
phosphate dehydrogenase (GAPDH) transcript using primers
XGAPD-5, 59-TGG TAT CGT GGA AGG ACT CA-39 and XGAPD-
3, 59-GTG TCG CTG TTG AAG TCA GA-39. Accordingly, the PCR
amplification was as follows; 30 s at 94 C˚, 30 s at 60 C˚ and 30 s
at 72 C˚ for 30 cycles using 1.5 units of Taq DNA polymerase
(Invitrogen). The PCR products were analysed by electrophor-
esis on 8% polyacrylamide gel. DNA was then transferred to a
nylon membrane (Hybond N+ Pharmacia, Amersham) by
Southern blotting. An internal oligonucleotide probe comple-
mentary to CFTR exon 10 and GAPDH exon 8 were labelled
with the radionucleotide27 32P using terminal deoxynucleotide
transferase (Invitrogen) according to the supplier’s conditions.
The blots were probed and the bands were visualised by
autoradiography. PCR products displaying altered mobility
were extracted using MiniElute Gel Extraction Kit (Qiagen)
and subjected to automated DNA sequencing analysis.
The minigene reporter systems CD44v5, CD44DL and
CD44DM were described previously.28 Seventeen nucleotides
flanking the wild-type and R553X alleles of exon 11 of the CFTR
gene were introduced into exon 5 of the CD44 gene by
overlapping extension using two rounds of PCR.29 The first
round of PCR fragments were amplified using 2 ml of Elongase
Enzyme mix (Invitrogen) for each of the three sets of constructs
(DL3911WT or R553X; DL5911WT or R553X; DM11WT or
R553X) using the following primers, CD44-F, 59-CAT GGA
TAA CCA TGT TCA GTC-39 and DL39WT/R553X-R, 59-TCT TGC
TCg/a TTG ACC TCT TCA TCC TGA TAC TCA TGG-39, DL59WT/
R553X-R or DMWT/R553X-R, 59-TCT TGC TCg/a TTG ACC TCT
TCG ATA TCA AGC TCG CGT C-39; and DL39WT/R553X-F, 59-
GA GGT CAA c/tGA GCA AGA TAC AAG CAC AAG TAA GAA
GG-39, DL59WT/R553X-F, 59-GAG GTC AAc/t GAG CAA GAC
CGG AAC CAC AGC CTC CTT TC-39 or DMWT/R553X-F, 59-GAG
GTC AAc/t GAG CAA GAC GAT GAA GAG GAG ACC CAC-39
and CD44-R, 59-TCC ACT AGT TCT AGC TAG AAG-39. The PCR
programme consisted of 20 cycles of 20 s at 94 C˚, 20 s at 60 C˚
(decreasing the annealing temperature by 0.5 C˚ per cycle) and
1 min at 68 C˚, followed by an additional 10 cycles of 20 s at
94 C˚, 20 s at 50 C˚ and 1 min at 68 C˚. The second round of PCR
was performed using the two corresponding fragments for each
of the three reporter systems and primers CD44-F and CD44-R
with 2 ml of Elongase Enzyme mix (Invitrogen). The PCR
programme used for the second round consisted of 20 cycles of
30 s at 94 C˚, 30 s at 50 C˚ (increasing the annealing temperature
0.5 C˚ per cycle) and 2 min at 68 C˚, followed by an additional 10
cycles of 30 s at 94 C˚, 30 s at 60 C˚ and 2 min at 68 C˚. The
resulting PCR fragments of 2490 bp were digested using BglII
and HpaI and cloned into the V5CD44DL and V5CD44DM,
respectively, using T4 DNA ligase (Invitrogen). The generated
minigene reporters were verified by sequencing.
Human embryonic kidney (HEK) 293 cells (from American
Type Culture Collection) were grown in Dulbecco’s modified
Eagle’s medium with high glucose supplemented with 10%
fetal calf serum and 1% streptomycin–penicillin antibiotics.
Human bronchial epithelial (IB3) cells30 were grown in LHC-8
medium with glutamine supplemented with 5% fetal calf serum
and 1% streptomycin–penicillin antibiotics. The cells were
grown in 10 cm tissue culture dishes.
A total of 4 mg of total plasmid DNA was transfected into HEK
293 and IB3 cells in replicates using lipofectamine reagent
(Invitrogen). After 18 h of transfection, the medium was
replaced with fresh complete medium. Cells were harvested
48 h after transfection. Total RNA was extracted as described
previously. Oligo dT-primed cDNA synthesis was preformed as
described previously. PCR amplification (30 s at 94˚ C, 30 s at
60˚ C and 30 s at 72˚ C for 30 cycles using 1.5 U of AmpliTaq DNA
polymerase (Boehringer Ingelheim)) of the fragment containing
CD44 exon 5 was performed using previously described
primers.28 The fragments were separated on a 2% agarose gel.
The ethidium bromide-stained band intensities were measured
by analysis of digitised images using AlphaEase V.5.1. Statistical
analysis was performed using GraphPad Prism 4.
RESULTS
Analysis of CFTR transcripts in patient cells carrying the
R553X mutation
We have performed transcript analysis of five patients with
cystic fibrosis who are compound heterozygotic for DF508
(1652del3, exon 10) and R553X (1789CRT) mutations. These
patient cell lines were used as the DF508 transcript has been
shown to be stable,31 and can be distinguished from transcripts
resulting from the R553X allele. Lymphoblastoid cell lines were
available, and we and others previously showed that the
splicing patterns of CFTR in these cell lines reflect those
observed in airway epithelia.11 32 Accordingly, total RNA was
extracted and a fragment spanning CFTR exons 10, 11 and 12
was analysed by reverse transcriptase-polymerase chain reac-
tion (RT-PCR) assays. Variable levels of an aberrantly spliced
form that corresponded to the skipping of exon 11 was
observed in all five patients with cystic fibrosis that was absent
in all control cell lines studied (fig 1A). Two of the three
previous studies have shown that no transcript is generated
from the R553X allele; however, it should be noted that for
one,25 the assay used would not have permitted the detection of
the exon 11 transcript and the second,26 did not use a sensitive
assay. The results from our study are consistent with the third
study12 that also showed that the R553X mutation causes
skipping of CFTR exon 11.
We assessed whether the skipped transcript (2exon 11)
generated from the R553X allele arises from nonsense-
associated altered splicing (NAS) and whether it is targeted
by the NMD pathway, as the exclusion of exon 11 results in a
frameshift that introduces a new PTC in exon 12. For this
purpose, the patient with cystic fibrosis and control cell lines
was treated with cycloheximide for 4 h before harvesting.
Cycloheximide, a protein synthesis inhibitor, has been reported
to inhibit NAS27 as well as NMD.33 If the – exon 11 transcript
were generated by NAS, a relative reduction of this transcript
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would be found in the presence of cycloheximide. If there were
no NAS, both the + exon 11 and – exon 11 transcripts would be
expected to increase in the presence of cycloheximide owing to
suppression of NMD. Results of transcript analysis showed an
increase in the overall levels for both the + exon 11 and – exon
11 transcripts as compared with endogenous GAPDH transcript
levels (fig 1A). Moreover, the expression of the – exon 11
transcript was apparently not reduced on cycloheximide
treatment. Although it should be kept in mind that the
efficiency with which cycloheximide blocks NAS and NMD
processes may vary, these results indicate that NAS is not likely
to be the underlying mechanism for exon skipping.
Subsequently, RT-PCR products spanning exons 10–12 from
cycloheximide-treated and untreated cell lines derived from
patient 2 (fig 1A) were sequenced. Results confirmed that the
full-length transcript was generated from the allele carrying the
DF508 mutation, although the transcript lacking exon 11
resulted exclusively from the R553X allele. In either cyclohex-
imide-treated or untreated cells of patient 2 (fig 1B) the R553X
allele was specifically aberrantly spliced. We cannot exclude the
possibility that low amounts of the R553X allele may lead to +
exon 11 transcript owing to limitations of detection by
sequencing analysis. Together, these results suggest that the
primary consequence of the R553X mutation is the skipping of
CFTR exon 11 and that it is not likely to be due to NAS.
Creation of a putative exonic splicing silencer element
by the R553X mutation
To elucidate more precisely the mechanism underlying R553X
mutation-associated exon skipping, a heterologous splicing
reporter construct was used. The reporter system was chosen
such that it allowed the assessment of sequences that promoted
(ESE) or hindered (ESS) exon inclusion. Briefly, it consisted of
three exons: two constant exons derived from the human
insulin gene that flank the alternatively spliced exon 5 (v5) of
the CD44 gene.28 In a previous study,28 two ESSs (L and M) and
one ESE (R) were defined by mutagenesis within the CD44 v5
exon (fig 2A). Typically, the intact exon v5 is efficiently
skipped, but removal of either of the two ESSs sequences (DL
and DM) increases the level of inclusion such that approxi-
mately 50% of the total CD44 reporter transcripts contain the
alternatively spliced exon.28 34 Splicing reporter cassettes were
generated to assess whether the R553X allele caused exon
skipping by disrupting an ESE or by creating an ESS
independently of other CFTR transcript features.
A region comprising 17 nucleotides surrounding the wild-
type (GAG GTC AAC GAG CAA GA) and R553X (GAG GTC AAT
GAG CAA GA) alleles of CFTR exon 11 was introduced into the
39 region of the CD44 reporter exon that lacked the first ESS
element (DL). This construct maintained the position of the
R553X mutation with respect to its distance from the 59 splice
site in CFTR exon 11 (fig 2B). The resulting constructs
DL3911WT and DL3911R553X in addition to the parental
construct (DL) were transfected into HEK 293 and IB3 cell
lines. Analyses of transcripts showed that there is a relative
increase in exon v5 skipping for DL3911R553X transcripts,
compared with DL3911WT transcripts (fig 2C, compare lanes 2
and 3 with 4 and 5). The ratios of exon inclusion/exclusion
from the wild-type and mutant constructs were found to be
significantly different (n = 4, p = 0.014; Mann–Whitney U test;
fig 2D), suggesting that the sequence carrying the R553X
mutation may act as a silencer element. It is interesting to note,
however, that both constructs containing CFTR sequences (wild
type and R553X) showed a dramatic increase in exon skipping
compared with the parental construct (DL; fig 2D). The 17-
nucleotide wild-type sequence may act as a negative element on
the splicing of the reporter exon, although the observed effect
probably reflects the disruption of the ESE (R) by the CFTR
sequences (fig 2B).
To evaluate these possibilities, we constructed additional
reporter cassettes in which the ESE (R) was specifically
deleted,28 maintaining the position of the CFTR wild-type or
the R553X mutation-containing sequences with respect to the
39 end of the exon (DR3911WT or DR3911R553X, respectively,
fig 2B). These constructs together with the parental construct
(DR) were transfected into HEK 293 cells. The results suggest
that the observed increase in exon skipping resulting from the
DL3911WT construct with respect to the parental DL construct
Figure 1 Analysis of transcripts from
patient cell lines carrying the R553X
mutation. (A) Reverse transcriptase-
polymerase chain reaction analysis of
lymphoblastoid cell lines derived from
patients with cystic fibrosis (P1-P5) carrying
the DF508/R553X genotype and controls
(C1–C3) separated by 8% polyacrylamide
gel. Cell lines were untreated (–) or treated
(+) with cycloheximide (100 mg/ml) for 4 h
before harvesting. Lower panel corresponds
to endogenous glyceraldehyde-3-phosphate
dehydrogenase (GAPDH) transcript. (B)
Schematic representation and sequences of
the + exon 11 and – exon 11 transcripts.
Rectangular boxes denote exons and short
lines denote sequencing primers. The
chromatographs correspond to the antisense
strand sequence of untreated PCR products
of patient 2. The upper chromatographs
show sequencing results of + exon 11
transcript, indicating the wild-type exon 11
sequence (R553 allele) and the DF508
(3 bp-deletion in exon 10) mutation only.
The lower chromatographs show that the
shorter transcript corresponds to the skipping
of exon 11, and that the DF508 mutation
does not occur in this transcript. P1–P5 =
patients 1–5, C1–C3 = controls 1–3, + exon
11 = full-length transcript, 2 exon 11 =
transcript that lacks exon 11.
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(fig 2D) was due to the disruption of the ESE (R) since only the
construct DR3911R553X showed an increase in exon skipping
relative to the parental construct (DR; fig 2E,F).
Together, these findings suggest that the R553X mutation
may result in the creation of an ESS element. Interestingly, the
sequence created by the R553X mutation (TCA AGG R TCA
ATG) partially resembles the consensus sequence of the ESS
‘‘PS10’’ (A/GAAATG) identified by Zhang and Chasin.20 In fact,
their analysis of a representative sequence of PS10 ESS by
mutagenesis (TAGAAATG R TAGAAAAG) showed a reduction
in ESS activity.20
Positional effect of the R553X mutation on exon
skipping
Given the proximity of the splicing element created by the
R553X mutation to the 39 end of exon 11, we hypothesised that
this putative negative element may affect 59 splice site selection.
To assess this, we introduced 17 nucleotides of exon 11 flanking
the wild-type (GAG GTC AAC GAG CAA GA) and R553X (GAG
GTC AAT GAG CAA GA) alleles into the 59 end (DL5911WT or
R553X) and middle (DM11WT or R553X) exon v5 segments
(fig 3A). These reporter constructs, in addition to the parental
constructs DL and DM, were transfected into HEK 293 cells.
Transcript analyses showed no marked changes in exon
skipping resulting from constructs carrying the wild-type or
R553X CFTR sequences near the 59 end or middle of the exon
(fig 3B,C). Moreover, no significant difference was observed
between the constructs carrying the CFTR sequences and either
parental constructs (DL and DM; fig 3B,C). These results
suggest that the element created by the R553X mutation does
not function as an ESS in the context of a 39 splice site and may
have a negative effect only on a proximal 59 splice site.
DISCUSSION
Skipping of exon 11 caused by the R553X mutation
through the creation of a position-dependent ESS
To date, more than 146 nonsense mutations identified in the
CFTR gene have been associated with severe cystic fibrosis
disease presentation (http://www.genet.sickkids.on.ca/cftr/).
Studies have shown that PTCs elicit nonsense-mediated
mRNA decay, a quality control mechanism that prevents the
expression of truncated proteins.9 10 There are examples,
however, where nonsense mutations are associated with exon
skipping.18 In the present study, we have investigated the CFTR
R553X mutation at the transcript level. Exon 11 skipping in
patients with cystic fibrosis that are compound heterozygotic
for DF508/R553X mutation was specifically associated with the
R553X mutation. The extent of exon skipping was variable but
Figure 2 Analysis of the consequences of the R553X mutation in a heterologous context indicates that it confers exonic splicing silencer (ESS) activity. (A)
Schematic representation of the splicing reporter construct.28 L = ESS1, M = ESS2, R = exonic splicing enhancers (ESE), ins 2 and 3 = insulin exons 2 and 3,
CD44V5 = exon v5 of the CD44 gene. (B) Schematic representation of the DL and DR constructs,28 in which 17 nucleotide sequences flanking the wild-type
allele (nt C) or the R553X allele (nt T) were introduced in the 39 segment of the CD44 exon v5, in the absence of ESS1 (L) or ESE (R) segments. The resulting
constructs were named DL3911WT and DR3911WT or DL3911R553X and DR3911R553X, respectively. The blackened DL or DR boxes denote the substitution
of each of these fragments of the CD44 exon v5 with BlueScript sequences as described elsewhere.28 (C) Reverse transcriptase-polymerase chain reaction
(RT-PCR) analyses of human embryonic kidney (HEK) 293 cell lines transfected with reporter constructs DL (lane 1), DL3911WT (lanes 2 and 3) and
DL3911R553X (lanes 4 and 5), respectively. A representative gel of two independent transfection experiments is shown. (D) Measurement of the resulting
PCR bands was carried out using AlphaEase V.5.1. The ratio of the band intensity corresponding to the +CD44V5 transcript over the band intensity
corresponding to the -CD44V5 transcript (inclusion/exclusion) within each lane was calculated. The bars correspond to the means and standard error
calculated for the ratios from four independent transfection experiments. The white bar corresponds to DL, the light grey bar corresponds to DL3911WT, and
the black bar corresponds to DL3911R553X transcripts. Mann–Whitney U test was performed using GraphPad Prism 4 indicating a statistically significant
increase in the skipping of CD44 exon 5 in the presence of cystic fibrosis transmembrane conductance regulator (CFTR) sequences carrying the R553X allele.
Similar results were obtained from transfection experiments using the human bronchial epithelial (IB3) cell line (data not shown). (E) RT-PCR analyses of HEK
293 cell lines transfected with reporter constructs DR (lane 1), DR3911WT (lanes 2 and 3) and DR3911R553X (lanes 4 and 5), respectively. (F) Measurement
of the resulting PCR bands was carried out as described in D. The bars correspond to the means and standard error calculated for the ratios from two
independent transfection experiments. The white bar corresponds to DR, the light grey bar corresponds to DR3911WT, and the black bar corresponds to
DR3911R553X transcripts. Results show an increase in the skipping of CD44 V5 in the presence of CFTR sequences carrying the R553X allele. All PCR
products in C and E were separated in a 2% agarose gel. + CD44V5, full-length transcript;2CD44V5, transcript lacking CD44 V5 exon; endo, endogenous
insulin transcript.
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maintained on cycloheximide treatment. These observations
exclude NAS as the cause for R553X-associated exon skipping.
We further investigated the underlying cause of the R553X
mutation-associated exon 11 skipping and showed that 17
nucleotides of exon 11 carrying the R553X mutation had a
negative effect on splicing in a heterologous reporter system
(CD44 v5 exon), compared with the wild-type allele. This effect
was only apparent when the R553X mutation was positioned
proximal to the 39 end of the exon, as occurs in CFTR exon 11.
The wild-type allele did not have a positive effect on the splicing
of CD44 exon 5, indicating that the R553X mutation did not
affect an ESE. Thus far, previous studies have shown that
nonsense mutations could affect splicing by disrupting
ESEs.16 18 Other reports have implicated a quality control
mechanism known as nonsense-associated altered splicing13 15
as the underlying cause of nonsense mutation-related exon
skipping. Our study provides the first evidence for a nonsense
mutation creating an ESS, and further shows that this putative
ESS element may result in exon skipping by preventing
selection of the proximal 59 splice site. Interestingly, the
sequence created by the R553X mutation partially resembles
the consensus sequence of an ESS previously identified by
Zhang and Chasin.20 A recent study has shown that the mode of
action of ESSs results in the silencing of 59 splice sites that are
located 39 of the ESS sequences.22 Although Wang et al22 also
showed that several such sequences resulted in the silencing of
39 splice sites located 59 of the ESSs (in addition to the silencing
of the 59 splice sites), one of them (hexamer ‘‘A’’, fig 1D22) only
influenced the 59 splice site.22 The putative ESS sequence
created by the R553X mutation seems to represent an
additional example of this latter mode of action of ESSs.
Therapeutic implications
Our findings have implications for proposed treatments for
nonsense mutations involving aminoglycoside antibiotics that
were shown to promote read-though of PTCs.23 24 Clinical trials
using gentamicin administered to patients with cystic fibrosis
carrying the W1282X mutation showed improvement of nasal
potential difference measurements and increased CFTR at the
cell membrane, compared with patients with cystic fibrosis
with non-nonsense mutations.24 However, our findings suggest
that nonsense mutations, such as CFTR R553X, which cause
exon skipping or are targeted by NMD, may not be good
candidates for such treatment. The results thus emphasise the
importance of determining the specific consequences of
nonsense mutations at the transcript level.
Molecular treatments directed against splicing defects are
being tested using various methods such as modified RNA
oligonucleotides,35 molecular chimeras,36 splicing factors37 and
chemical compounds.38 It was recently shown that 29-O-methyl
antisense oligonucleotides (29OMeAOs) directed against the
Duchenne muscular dystrophy gene systemically delivered to
the dystrophic mdx mouse caused the skipping of an exon
carrying a nonsense mutation, leading to an improvement in
muscle function.35 These results suggest that 29OMeAOs could
also be used to treat patients with splicing defects. Similarly, it
may be possible to treat the splicing defect caused by the R553X
mutation using a 29OMeAO directed against the region where
the mutation is located in CFTR exon 11, to prevent the binding
of splicing factors responsible for exon 11 skipping. The
correction would lead to the presence of CFTR transcripts
carrying exon 11 generated from the R553X allele, and provided
it is not entirely degraded by NMD, it could then be treated
using aminoglycoside antibiotics.
ACKNOWLEDGEMENTS
We thank Dr Andrew Paterson for advice on statistical analyses. The
work was supported by a grant from the Canadian Cystic Fibrosis
Foundation (CCFF) to L-CT and JZ. IA was the recipient of CCFF
Studentship and The Hospital for Sick Children research training
awards. BJB was supported by grants from the Canadian Institutes of
Health Research.
Figure 3 Position effect of the R553X mutation. (A) Schematic representation of the CD44V5 DL and CD44V5 DM constructs described elsewhere,28 in
which 17 nucleotide sequences flanking the wild-type allele (nt C) or the R553X allele (nt T) were introduced at the 59 and in the middle segments of CD44
exon v5. The resulting constructs were named DL5911WT and DM 11WT or DL5911R553X and DM11R553X, respectively. ins 2 and 3 = insulin exons 2
and 3, CD44V5 = exon 5 of the CD44 gene. DL or DM in black boxes denote the substitution of the L (exonic splicing silencer (ESS)1) or M (ESS2) segments
of the CD44 exon v5, respectively, with BlueScript sequences as described elsewhere.28 (B) Reverse transcriptase-polymerase chain reaction (RT-PCR)
analysis of human embryonic kidney (HEK) 293 cell lines transfected with reporter constructs DL (lane 1), DL5911WT (lane 2), DL5911R553X (lane 3), DM
(lane 4), DM11WT (lane 5) and DM11R553X (lane 6), respectively. PCR products were separated in a 2% agarose gel. + CD44V5 = full-length transcript,
2CD44V5 = transcript lacking CD44 exon 5. (C) Measurement of the resulting PCR bands was carried out as described in fig 2D. The bars correspond to
the means and standard error calculated for the ratios from two independent transfection experiments. The white bar corresponds to the DL or D M, the light
grey bars correspond to DL5911WT and DM11WT and the black bars correspond to DL5911R553X and DM11R553X transcripts.
Key points
N The third most common nonsense mutation in the cystic
fibrosis transmembrane conductance regulator gene,
R553X (1789CRT), was found to cause exon 11
skipping in cell lines from patients with cystic fibrosis.
N The R553X mutation-associated exon skipping did not
seem to result from nonsense-associated altered splicing.
N The R553X mutation caused exon skipping through
the creation of a position-dependent exonic splicing
silencer.
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